Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Placebo-Controlled, Phase 2a, Proof-of-Concept Study to Evaluate Efficacy, Safety, and Tolerability of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT05629208 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT05629208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05629208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Placebo-Controlled, Phase 2a, Proof-of-Concept Study to Evaluate Efficacy, Safety, and Tolerability of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE)
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Terminated
Start date
April 17, 2023
Completion date
January 14, 2026
Enrollment
20 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous lupus erythematosus (cle)